AnaptysBio

ANABPhase 2

AnaptysBio is a clinical-stage biotech advancing a pipeline of best-in-class antibodies designed to dampen inflammatory responses and restore immune balance in autoimmune and inflammatory diseases. The company has demonstrated its antibody discovery capabilities through out-licensed assets like Jemperli (GSK) and imsidolimab (Vanda Pharmaceuticals), which provide royalty revenue. Strategically, AnaptysBio has announced its intent to separate its biopharma operations from its royalty assets by year-end 2026, aiming to create two distinct investment vehicles focused on development and financial assets, respectively.

Market Cap

$1.8B

Focus

AntibodiesBiologics

ANAB · Stock Price

USD 62.37+37.10 (+146.79%)

Historical price data

AI Company Overview

Technology Platform

Proprietary antibody discovery and development platform focused on immune cell modulation to generate best-in-class antibodies against high-value immunological targets.

Pipeline Snapshot

8 drugs in pipeline

Drug	Indication	Stage
Rosnilimab + Placebo	Rheumatoid Arthritis	Phase 2
Etokimab + Placebo + Mometasone Furoate Nasal Spray	Chronic Rhinosinusitis	Phase 2
Rosnilimab + Placebo	Alopecia Areata	Phase 2
ANB032 + Placebo	Atopic Dermatitis Eczema	Phase 2
Etokimab + Placebo	Peanut Allergy	Phase 2

Opportunities

The planned separation of royalty assets could unlock value and provide dedicated capital for pipeline development.

Positive Phase 1 data for ANB033 or rosnilimab would significantly de-risk these programs and enable advancement into larger trials.

The established royalty stream from Jemperli provides a financial foundation to fund operations.

Risk Factors

High clinical risk as all core programs are in early Phase 1.

Intense competition in autoimmune diseases, especially rheumatoid arthritis.

Execution risk associated with the complex corporate separation.

Dependence on partner GSK for Jemperli royalty revenue and ongoing litigation related to that agreement.

Competitive Landscape

Faces competition from established biologics and new entrants in celiac disease, eosinophilic esophagitis (e.g., dupilumab), and a crowded rheumatoid arthritis market. Differentiation strategy relies on developing best-in-class antibody profiles with precise immune cell modulation to achieve deeper and more durable responses in targeted patient populations.

Publications

Patents

Pipeline